cases. Age (p[0.011), Pathological Gleason (P<0.001) and Stage (p[0.010) were predictive of BCR. Adjuvant or Salvage Radiotherapy was required in 63 (13.7%) cases. Overall, there were 57 (12.4%) deaths; 10 (2.17%) died of prostate cancer with a median survival of 8.3yrs.
INTRODUCTION AND OBJECTIVES:
Male stress urinary incontinence is a well-recognized complication after radical prostatectomy in patients with prostate cancer. Although deterioration of storage symptoms such as urgency and frequency is also expected after radical prostatectomy, few studies have evaluated storage dysfunction such as overactive bladder (OAB) after radical prostatectomy. In this study, we evaluated an incidence of de novo OAB and the factors related to de novo OAB occurrence following radical prostatectomy.
METHODS: We prospectively observed the patients without OAB who underwent radical prostatectomy for prostate cancer in our institution from October 2017 to March 2018. All the patients underwent international prostate symptom score (IPSS), overactive bladder symptom score (OABSS), and uroflowmetry before surgery and at three months after surgery. OAB was defined as a score of 1 or more of the urgency component of OABSS. At three months after radical prostatectomy, the patients were divided into two groups (OAB group and non-OAB group) on the presence of de novo OAB. We evaluated the patients' demographics and outcomes after radical prostatectomy according to de novo OAB. Predictive factors for de novo OAB after radical prostatectomy were analyzed using a multivariate logistic regression model. RESULTS: Of the 50 patients without pre-operative OAB, de novo OAB was observed in 22 (44%) patients at 3 months after radical prostatectomy. De novo OAB group showed old age, high value of preoperative IPSS storage subscore, and large volume of post-void residual urine on preoperative uroflowmetry compared to non-OAB group. Multivariate analysis showed that age and preoperative IPSS storage subscore were independent predictive factors of de novo OAB after radical prostatectomy. Preoperative risk stratification for prostate cancer, method of radical prostatectomy (open vs robot), and pathological results were not related with de novo OAB following radical prostatectomy.
CONCLUSIONS: In this study, de novo OAB was observed in 44% (22/50) patients at 3 months after radical prostatectomy. Age and preoperative IPSS storage subscore were found to be independent predictive factors of de novo OAB following radical prostatectomy. CONCLUSIONS: Patients with BNS had a better chance to be pad-free at 7-days after catheter removal and had a significant shorter time to catheter removal. However, this beneficial effect disappeared with time and no differences in continence rates at 3 months and 1 year were recorded. Moreover, BNS did not negatively affect positive margin or BCR rates.
Source of Funding: None

MP60-08 INCIDENCE OF PATHOLOGICAL HIGH GRADE AND STAGE CANCERS IN PATIENTS DIAGNOSED WITH MICROFOCAL ADENOCARCINOMA OF THE PROSTATE AT BIOPSY: A MULTICENTER STUDY
INTRODUCTION AND OBJECTIVES: Localized low-risk prostate cancer (PCa) can have different biological behaviour and its treatment remains controversial. We investigated the incidence of unfavorable features (defined as ISUP Grade ! 3 and/or stage ! pT3a) after radical prostatectomy (RP), in patients initially diagnosed with microfocal PCa (miPCa) at prostate biopsy (PBx).
METHODS: The current multicenter study included patients diagnosed with miPCa at PBx and having undergone RP. miPCa was defined as a single positive focus 3 mm. Patients were stratified according to the D'Amico risk classification and surgical approach (retropubic, laparoscopic, and robot assisted RP).
RESULTS: Overall 647 patients were included: 461, 139 and 47 patients were classified as low-, intermediate-and high-risk according to the D'Amico risk classification, respectively. Mean age was 65.7 years. Mean PSA was 8.25 ng/ml and PSAD was 0.18. Overall 242 (37.4%) patients were upgraded after RP. Unfavorable characteristics were found in 172 (26.6%), 91 (52.9%) of which were previously classified as low-risk patients. 159 (34.5%) low-risk patients were upgraded after RP: an ISUP Grade ! 3 PCa was diagnosed in the 32.7% of them (42, 5 and 5 patients with ISUP Grade 3, 4 and 5 respectively). Moreover 113 (17.5%) patients had an extraprostatic extension of the cancer (pathological stage ! pT3a) and 119 (19.2%) had positive surgical margins. Overall 360 (55.6%), 203 (31.4%) and 84 (13.0%) patients had undergone retropubic, laparoscopic and robot assisted RP. Interestingly, no significant differences were reported in positive surgical margins incidence according to the surgical approach (p [ 0.116), despite the different usage of the nerve sparing technique (35.6, 44.3 and 67.8% in retropubic, laparoscopic and robot assisted RP, respectively) . It is also notable that 1 (0.2%) patient, previously diagnosed with a GS 6 PCa, was definitively classified as pT0 after RP. The ROC curve analysis demonstrated that PSA, PSAD, and D'Amico risk classification had an AUC value of 0.628, 0.681, and 0.631 respectively to predict the risk of unfavorable features. The PSAD had the best predictive ability, significantly higher than PSA METHODS: 9,742 patients who underwent RP between 2000 and 2017 with or without PLND were identified in a multi-institutional database of four centers. Only patients with more than 5% risk of lymph node invasion according to the Briganti nomogram were included. Univariable and multivariable Cox regression models tested the effect of extended PLND on biochemical recurrence (BCR), clinical recurrence (CR) and cancer-specific mortality (CSM). All analyses were repeated after propensity score matching. Matching was performed for pathologic primary Gleason, pathologic tumor stage, prostate specific antigen (PSA) and surgical margin.
RESULTS: Overall, 707 (7.3%) patients did not undergo PLND. Of those, 520 vs. 187 harbored D'Amico high-or intermediate-risk characteristics, respectively. Individuals without PLND had significantly lower median PSA and more frequently harbored biopsy
